<DOC>
	<DOCNO>NCT03066804</DOCNO>
	<brief_summary>The purpose study demonstrate superiority LCZ696 individualize medical therapy comorbidities reduce N-terminal pro-brain natriuretic peptide ( NT-proBNP ) improve HF symptom functional capacity patient heart failure preserve ejection fraction ( HFpEF ) .</brief_summary>
	<brief_title>A Randomized , Double-blind Controlled Study Comparing LCZ696 Medical Therapy Comorbidities HFpEF Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Angiotensin II Type 1 Receptor Blockers</mesh_term>
	<criteria>Left ventricular ejection fraction ( LVEF ) ≥45 % echo within 6 month prior study entry screen epoch Symptom ( ) heart failure ( HF ) require treatment diuretic ( include loop , thiazide diuretic , mineralocorticoid antagonist [ MRAs ] ) least 30 day prior study entry NYHA class IIIV Structural heart disease ( left atrial enlargement leave ventricular hypertrophy ) document echocardiogram . NTproBNP &gt; 220 pg/mL patient atrial fibrillation/atrial flutter ( AF ) &gt; 600 pg/mL patient AF KCCQ clinical summary score &lt; 75 Patients ACEi ARB therapy must history HTN Any prior measurement LVEF &lt; 40 % Acute coronary syndrome ( include MI ) , cardiac surgery , major CV surgery within 3 month , urgent percutaneous coronary intervention ( PCI ) within 3 month elective PCI within 30 day prior study entry Any clinical event within 6 month prior Visit 1 could reduce LVEF ( eg MI , coronary artery bypass graft [ CABG ] ) , unless echo measurement perform event confirm LVEF ≥ 40 % EF ≥ 45 % time screen Current acute decompensated HF require therapy . Current use renin inhibitor ( ) History hypersensitivity LCZ696 components Patients known history angioedema Walking distance primarily limit noncardiac comorbid condition Alternative reason shortness breath : significant pulmonary disease severe COPD , hemoglobin ( Hgb ) &lt; 10 g/dL male &lt; 9.5 g/dL female , body mass index ( BMI ) &gt; 40 kg/m^2 . Systolic blood pressure ( SBP ) ≥ 180 mmHg study entry , SBP &gt; 150 mmHg &lt; 180 mmHg study entry unless patient receive 3 antihypertensive drug , SBP &lt; 110 mmHg study entry . Patients HbA1c &gt; 7.5 % treat diabetes Patients prior major organ transplant intent transplant ( ie transplant list ) eGFR &lt; 30 ml/min/1.73 m^2 measure MDRD screen Serum potassium &gt; 5.2 mmol /L study entry History presence disease life expectancy &lt; 3 year Pregnant nursing woman woman childbearing potential unless use highly effective method contraception Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Cardiovascular Diseases</keyword>
	<keyword>Heart Failure</keyword>
	<keyword>Heart failure Preserved Ejection Fraction</keyword>
	<keyword>NT-proBNP</keyword>
	<keyword>KCCQ</keyword>
	<keyword>6 MWT</keyword>
	<keyword>SF-36</keyword>
	<keyword>NYHA Class</keyword>
	<keyword>LCZ696</keyword>
	<keyword>Enalapril</keyword>
	<keyword>Valsartan</keyword>
	<keyword>Angiotensin-Converting Enzyme Inhibitors ( ACEi )</keyword>
	<keyword>Angiotensin II Type 1 Receptor Blockers ( ARB )</keyword>
	<keyword>Renin Angiotensin System Inhibitors ( RASi )</keyword>
</DOC>